Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OraSure Technologies Announces 2020 Annual Meeting Date

OSUR

BETHLEHEM, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:  OSUR) today announced that its 2020 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 19, 2020.  The record date for the Meeting will be March 27, 2020.  Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2020 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting.  This will be a completely virtual meeting, conducted as a live webcast.  Further details regarding the Meeting will be provided at a later date.

About OraSure Technologies

OraSure Technologies is empowering the global community to improve health and wellness by providing access to accurate essential information.  OraSure is a leader in the development, manufacture and distribution of point-of-care diagnostic tests, molecular collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick® platform, sample self-collection and stabilization products for molecular applications, and oral fluid laboratory tests for detecting various drugs of abuse. Together with its wholly-owned subsidiaries (DNA Genotek, CoreBiome, Novosanis and Diversigen), OraSure provides its customers with value-added, end-to-end solutions that encompass tools, diagnostics and services.  OraSure’s portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities and consumers. For more information on OraSure Technologies, please visit www.orasure.com.

For more information on OraSure Technologies, please visit www.orasure.com.

Investor Contact:
Roberto Cuca, Chief Financial Officer
(610) 882-1820
investorinfo@orasure.com

Primary Logo